Today: 19 November 2025
Subscribe
Browse Tag

Biotech

Cidara Therapeutics (CDTX) Surges on Accelerated Flu Drug Trial – Key Updates for Investors

Merck’s $9.2 Billion Bid Sends Cidara Therapeutics (CDTX) Soaring 105% on November 14, 2025

Cidara Therapeutics, Inc. (NASDAQ: CDTX) is at the center of Wall Street’s attention today after Merck & Co., Inc. (NYSE: MRK) agreed to acquire the San Diego–based biotech in a cash deal valued at approximately $9.2 billion, sending CDTX shares more than 100% higher in a single session. Reuters+1 Below is a detailed look at today’s news (14 November 2025), the science behind Cidara’s lead flu-prevention asset CD388, the stock market reaction, and the wave of shareholder-law-firm investigations that emerged within hours of the announcement. Merck to Acquire Cidara for $221.50 Per Share in Cash Merck and Cidara announced this
14 November 2025
 ·  ·  ·  ·  ·  · 
Cytek Biosciences (CTKB) Stock Pops in Choppy Market After String of Positive Catalysts – November 14, 2025

Cytek Biosciences (CTKB) Stock Pops in Choppy Market After String of Positive Catalysts – November 14, 2025

On Friday, November 14, 2025, Cytek Biosciences, Inc. (NASDAQ: CTKB) is trading sharply higher, extending a strong two‑week run helped by fresh industry recognition, product awards and steady (if modest) earnings growth. As of the latest trade this afternoon, CTKB is changing hands around $4.99, up roughly 9% intraday, with the stock appearing on Nasdaq’s list of notable movers even as the broader U.S. market trades lower. Benzinga Below is a breakdown of all the key Cytek‑related news impacting CTKB today, November 14, 2025, plus the most important headlines from the past few days that are driving sentiment. 1. What’s
14 November 2025
 ·  ·  ·  ·  · 
Salarius Pharmaceuticals (SLRX) Stock Jumps as $7M Offering Prices; Closing Expected November 12, 2025 Amid Decoy Therapeutics Merger

Salarius Pharmaceuticals (SLRX) Stock Jumps as $7M Offering Prices; Closing Expected November 12, 2025 Amid Decoy Therapeutics Merger

Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX) is back in the headlines today after pricing a $7 million underwritten public offering tied to its pending business combination with Decoy Therapeutics. The company said the deal is expected to close “on or about November 12, 2025,” pending customary conditions, including consummation of the Decoy transaction. PR Newswire Key takeaways What happened today (Nov. 12, 2025) Salarius confirmed the pricing of its offering for gross proceeds of ~$7 million before fees. The package includes: The company notes the registration statement on Form S‑1 (File No. 333‑284368) became effective on Nov. 10, 2025, and the
12 November 2025
 ·  ·  ·  · 
Moderna (MRNA) Beats Q3 on Sales of New COVID Shot, Trims 2025 Outlook; Stock Whipsaws — Nov. 6, 2025

Moderna (MRNA) News Today—November 11, 2025: UBS Sees 2026 Upside, Redburn Cuts PT to $36, Bernstein Stays Market Perform After Cost Cuts

Published: November 11, 2025 Moderna, Inc. (NASDAQ: MRNA) drew multiple analyst headlines today as Wall Street recalibrated views in the wake of last week’s earnings and ongoing cost‑cutting. UBS highlighted potential 2026 upside on pipeline and expense discipline; Redburn Atlantic trimmed its price target; and Bernstein reiterated a neutral stance. Shares traded higher during the U.S. session alongside the commentary. MarketScreener+2MarketScreener+2 Today’s key headlines Stock move: By mid‑session, MRNA traded notably higher—around the mid‑single digits—amid the day’s analyst chatter. Investing.com Why these calls matter Investors are still digesting Q3 2025 results from November 6, when Moderna posted a narrower‑than‑expected loss
11 November 2025
 ·  ·  ·  ·  · 
Intellia Therapeutics (NTLA) plunges after patient death in pivotal CRISPR trial; Q3 update, analyst downgrades and what to watch next [Nov. 7, 2025]

Intellia Therapeutics (NTLA) plunges after patient death in pivotal CRISPR trial; Q3 update, analyst downgrades and what to watch next [Nov. 7, 2025]

What happened today Intellia Therapeutics (NASDAQ: NTLA) is under intense pressure after the company said the patient who experienced Grade 4 liver enzyme and bilirubin elevations in its Phase 3 MAGNITUDE study later died. In a Nov. 6 business update, CEO John Leonard said the treating physician cited “complicating comorbidities,” and Intellia is working with investigators and outside experts on a risk‑mitigation plan for nexiguran ziclumeran (nex‑z; NTLA‑2001), its in vivo CRISPR therapy for transthyretin amyloidosis (ATTR). The FDA’s clinical holds on MAGNITUDE (ATTR‑CM) and MAGNITUDE‑2 (ATTR‑PN) are still in effect pending a formal hold letter. GlobeNewswire+1 Sell‑side reaction was
7 November 2025
 ·  ·  ·  ·  · 
Novavax (NVAX) Raises 2025 Revenue Outlook After Q3 Beat; Sanofi Milestones Drive Guidance — November 6, 2025

Novavax (NVAX) Raises 2025 Revenue Outlook After Q3 Beat; Sanofi Milestones Drive Guidance — November 6, 2025

What happened today Novavax, Inc. (NASDAQ: NVAX) reported Q3 2025 results and raised its full‑year adjusted revenue framework to $1.04–$1.06 billion (from $1.00–$1.05 billion). Management cited momentum from licensing, supply, and milestone revenue—while excluding Sanofi‑led sales and royalties from the outlook. The company also reaffirmed 2025 operating‑expense guidance. ir.novavax.com Revenue for the quarter came in at $70 million, above Wall Street expectations, while the GAAP net loss widened to $202 million year‑over‑year, reflecting $126 million in non‑cash charges, including $97 million related to a previously announced Maryland facility consolidation. Reuters On a per‑share basis, Novavax posted a GAAP loss of
6 November 2025
 ·  ·  ·  · 
From Crash to Breakthrough: Why Lunai Bioworks (LNAI) Is Suddenly on Investors’ Radar

From Crash to Breakthrough: Why Lunai Bioworks (LNAI) Is Suddenly on Investors’ Radar

Company Overview: AI-Powered Biotech at the Intersection of Therapeutics & Biodefense Lunai Bioworks Inc. is a pre-clinical stage biotechnology company pioneering an unusual dual focus: AI-driven drug discovery and biodefense. The company’s mission is to “capture biological signals at scale, decode them with AI, and rapidly validate insights in model systems”, bridging cutting-edge computation with experimental biotech ainvest.com ainvest.com. In practical terms, Lunai is developing both therapeutic platforms (for diseases like cancer and neurodegeneration) and advanced diagnostics/screening tools (including detecting chemical/biological threats), all underpinned by machine learning. Core Technology & Pipeline: Lunai’s flagship approach is a next-generation allogeneic dendritic cell
5 November 2025
 ·  ·  ·  ·  · 
Biohaven (BHVN) Stock Plunges on FDA Setback – Will Its Biotech Pipeline Fuel a Comeback?

Biohaven (BHVN) Stock Plunges on FDA Setback – Will Its Biotech Pipeline Fuel a Comeback?

FDA Setback: Complete Response Letter Halts Lead Drug Ambitions Biohaven’s recent troubles center on VYGLXIA (troriluzole) – its lead drug candidate for spinocerebellar ataxia (SCA), a degenerative brain disorder that currently has no approved treatment reuters.com. On November 4, 2025, after market close, Biohaven announced that the FDA had issued a Complete Response Letter (CRL) rejecting the company’s New Drug Application. This CRL cited multiple concerns with Biohaven’s data: potential bias, design limitations, lack of pre-specification, and unmeasured confounding factors in the supporting studies stocktwits.com stocktwits.com. In simpler terms, the FDA was uneasy with how Biohaven ran and analyzed its
5 November 2025
 ·  ·  ·  ·  · 
Roche’s $3.5B Bet on 89bio (ETNB) – Stock Soars to New Highs as NASH Breakthrough Looms

Roche’s $3.5B Bet on 89bio (ETNB) – Stock Soars to New Highs as NASH Breakthrough Looms

Recent Developments and News (Nov 2025) 89bio has dominated biotech headlines in late 2025 due to Roche’s takeover move. On October 30, 2025, Roche announced it had successfully completed a tender offer for 89bio at $14.50/share + a $6.00 CVR, and would immediately merge 89bio into its subsidiary roche.com investing.com. By acquiring over 60% of shares in the tender (and securing another ~27% via guaranteed delivery), Roche was able to execute a short-form merger without a shareholder vote investing.com investing.com. All remaining ETNB shares will convert into the same $14.50 + CVR deal, and 89bio’s stock will cease trading on Nasdaq investing.com
5 November 2025
 ·  ·  ·  · 
Luxury Boom vs. Fed Gloom: European Markets Whipsaw (Sept 23–24, 2025)

5 Stocks You Need to Buy Now (November 4, 2025) – Tech, Energy, Biotech & More

Key Takeaways (November 4, 2025) <br> Table: Key Metrics for Top 5 Stocks (Nov 4, 2025) Company (Ticker) Price (Nov 4, 2025) Market Cap Trailing P/E Forward P/E Dividend Yield Amazon.com (AMZN) ~$254 morningstar.com $2.60 T macrotrends.net ~34× finance.yahoo.com ~29× finance.yahoo.com N/A (growth) JPMorgan Chase (JPM) ~$309 marketbeat.com $850 B marketbeat.com 15.3× marketbeat.com ~17× (est.) 1.9% marketbeat.com Eli Lilly (LLY) ~$863 investing.com $803 B stockanalysis.com 53.6× finance.yahoo.com 27.2× finance.yahoo.com ~0.7% macrotrends.net Exxon Mobil (XOM) ~$114 reuters.com $488 B macrotrends.net 15.8× finance.yahoo.com 15.0× finance.yahoo.com 3.6% marketbeat.com Alibaba Group (BABA) ~$168 finance.yahoo.com ~$375 B stockanalysis.com ~17× seekingalpha.com 9.8× nasdaq.com N/A (reinvesting) (Market caps in USD; P/E =
4 November 2025
 ·  ·  ·  · 
Scienture Holdings (SCNX) Surges on Coverage Breakthrough – Can This Pharma Underdog Deliver?

Scienture Holdings (SCNX) Surges on Coverage Breakthrough – Can This Pharma Underdog Deliver?

Company Profile & Background Scienture Holdings, Inc. is a tiny specialty pharmaceutical company focused on developing and commercializing novel formulations that address unmet needs in healthcare globenewswire.com globenewswire.com. The company’s roots trace back to a 2024 merger with TRxADE Health, a drug marketplace business – after which the combined entity rebranded as Scienture (NASDAQ: SCNX) nasdaq.com. In early 2025, management decisively pivoted to pharma: selling off legacy pharmacy/IT subsidiaries for $5 million to free up resources and “dedicate full focus” to its specialty drug pipeline globenewswire.com globenewswire.com. Today Scienture is headquartered in Tampa, FL (with R&D operations in New York)
4 November 2025
 ·  ·  ·  · 
Sarepta Therapeutics (SRPT) Surges After FDA Greenlights Duchenne Gene Therapy – Is a Rebound Ahead?

Sarepta (SRPT) Stock Collapses 80% on FDA Bombshell – Is a Big Rebound Coming?

SRPT Stock Price & Recent Performance Sarepta’s stock has experienced a dramatic collapse in 2025, wiping out years of gains. After starting the year near all-time highs, SRPT shares have plunged by over 80% year-to-date marketbeat.com. As of early November 2025, the stock trades in the mid-teens, down from about $120–$130 at the start of the year. In fact, the stock’s 52-week range tells the story: it hit a high of $138.81 and a low of just $10.41 over the past year marketbeat.com. This implosion has vastly underperformed the biotech sector (for context, the biotech index is up ~19% in
4 November 2025
 ·  ·  ·  ·  · 
1 2 3 … 11
Go toTop